TAK

Takeda Pharmaceutical Co Ltd: FY2026 Financial Summary

Business Context and Reporting Period

This Form 6-K filing reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the fiscal year ended March 31, 2026 (FY2026). The company is a global R&D-driven biopharmaceutical firm focused on gastrointestinal, neuroscience, oncology, rare diseases, plasma-derived therapies, and vaccines. The filing includes an English translation of the Earnings Report (Kessan Tanshin) and an additional provision for legal proceedings.

Key Financial Metrics

Material Changes vs. Prior Period

• Legal Provision Impact: The primary driver of the reported net loss was a JPY 403.5 billion provision for legal proceedings recorded in "Other Operating Expenses" following a jury verdict in the U.S. AMITIZA antitrust litigation. This caused Operating Profit to collapse from JPY 342.6 billion to JPY 6.2 billion.
• Revenue Decline: Total revenue decreased 1.7% (AER), primarily due to a 26.8% decline in the Neuroscience segment driven by generic erosion of VYVANSE in the U.S. This was partially offset by growth in Gastroenterology (+3.7%), Plasma-Derived Therapies (+2.4%), and Oncology (+3.5%).
• Core Performance: Excluding the legal provision and other non-core items, Core Operating Profit increased 0.8% to JPY 1,172.5 billion, and Core EPS rose 5.2% to JPY 517, indicating underlying operational stability.
• Impairment Losses: The company recorded JPY 90.1 billion in impairment losses, including JPY 58.2 billion for the discontinuation of a gamma delta T-cell therapy platform and JPY 31.9 billion related to ALUNBRIG.
• Balance Sheet: Total provisions increased by JPY 467.7 billion due to the legal litigation. Cash and cash equivalents increased significantly to JPY 595.1 billion, supported by strong operating cash flows and reduced financing outflows.

Guidance, Outlook, and Risks

• FY2027 Forecast:
  • Revenue: Forecast at JPY 4,640.0 billion (+3.0% YoY).
  • Operating Profit: Forecast at JPY 420.0 billion (significant recovery from FY2026 due to the one-time legal charge in the prior year).
  • Net Profit: Forecast at JPY 166.0 billion.
  • Core Operating Profit: Forecast at JPY 1,160.0 billion (-1.1% YoY).
  • Core EPS: Forecast at JPY 472 (-8.7% YoY).
• Management Guidance (Constant Exchange Rate):
  • Core Revenue: Low-single digit % decline.
  • Core Operating Profit: 5% to 8% decline.
  • Core EPS: Mid-teens % decline.
• Dividends: Annual dividend for FY2026 set at JPY 200 per share. FY2027 guidance is JPY 204 per share.
• Risks and Contingencies:
  • AMITIZA Litigation: A jury awarded plaintiffs USD 884.9 million in single damages (subject to trebling). Takeda intends to appeal. The company does not expect this to materially impact FY2027 forecasts but will monitor proceedings.
  • Generic Erosion: Continued pressure on VYVANSE and RESOLOR/MOTEGITY in the U.S.
  • Regulatory Environment: Pricing pressures and policy changes in the U.S. (Medicare Part D redesign) and Europe.

Key Facts for Investor Verification

• Legal Liability Finalization: Verify the status of the AMITIZA antitrust appeal and the potential for trebled damages (approx. USD 2.6 billion) to impact future cash flows or provisions.
• VYVANSE Trajectory: Monitor the rate of generic erosion for VYVANSE in the U.S. and its impact on the Neuroscience segment's revenue recovery.
• Core Margin Compression: Investigate the drivers behind the forecasted 5-8% decline in Core Operating Profit and mid-teens decline in Core EPS for FY2027 despite revenue growth.
• Debt Management: Review the company's strategy to reduce the adjusted net debt to adjusted EBITDA ratio to the targeted 2x, given the current debt level of JPY 4.88 trillion.
• Product Launches: Track the regulatory approval and commercial launch timeline for key pipeline assets: oveporexton, rusfertide, and zasocitinib, which are critical for the "Horizon Two" growth strategy.